mumps
MUMPS
Mumps is a self-limited viral disease characterized by nonsuppurative swelling and tenderness of one or both parotid glands.
It commonly affects the children aged 2-12 years and very uncommon in <1 year of age.
It is caused by a single-stranded RNA virus classified under Paramyxoviridae family or mumps virus.
Transmission is through airborne droplets from respiratory secretion of infected persons.
Incubation period is typically 14-21 days.

Mumps Treatment

Pharmacotherapy

Analgesics & Antipyretics

  • Eg Paracetamol, Ibuprofen
  • May be given to relieve fever & discomfort

Non-Pharmacological Therapy

  • Bed rest: Hospitalization is needed for severe orchitis
  • Warm or cold packs over inflamed parotid to relieve discomfort
  • IV fluid administration for patients w/ persistent vomiting
  • “Bridge” support & ice packs, in addition to analgesics, may help relieve orchitis if present
  • Lumbar puncture may help relieve headache associated w/ meningitis, if present
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Roshini Claire Anthony, 24 Feb 2021

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not result in worsening renal function or bone mineral density (BMD) in Asian patients with chronic hepatitis B virus (HBV) infection, according to a small real-world prospective study.

Roshini Claire Anthony, 6 days ago

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.